Biopharmaceutical firm Cytogen has begun a new clinical development initiative for a targeted oncology product designed to treat prostate and other cancers.
The product candidate employs DOTA-based bifunctional chelant technology to radiolabel Cytogen's proprietary monoclonal antibody to prostate-specific membrane antigen (PSMA) with a therapeutic radionuclide, according to the Princeton, NJ-based firm.
By AuntMinnie.com staff writers
April 4, 2005
Related Reading
Cytogen hires medical affairs VP, December 13, 2004
Advanced Magnetics, Cytogen get FDA nod, October 20, 2004
Cytogen notches record revenues, August 6, 2004
Cytogen may join Russell 3000, June 14, 2004
Copyright © 2005 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
